News
Chemed To Report First-Quarter 2022 Earnings April 26, Related Conference Call To Be Held On April 27
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2022, on Tuesday, April 26, 2022, following the close of trading on the
Dexcom Publishes Annual Sustainability Report
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its third annual Sustainability Report. This report
DGAP-HV: STRATEC SE: Bekanntmachung der Einberufung zur Hauptversammlung am 20.05.2022 in Virtuelle Hauptversammlung mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
AEVIS VICTORIA SA - Ordentliche Generalversammlung vom 28. April 2022
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders on 28 April 2022
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second
AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022
AMN Healthcare Services, Inc. (NYSE: AMN) has scheduled a conference call to discuss its first quarter 2022 financial results and second quarter 2022 outlook on Thursday, May 5, 2022 at 5:00 p.m
Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 third quarter on Tuesday, May 3, 2022, at approximately 6:30 a.m. ET. The company will also
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)
Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma
Agilent Technologies Inc. (NYSE: A) today announced it has expanded CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx as an aid in identifying esophageal squamous cell carcinoma
Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
Agilent Joins AMBIC to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC). Joining AMBIC demonstrates the company’s
Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that its Board of Directors has named Christopher Hunter as the Company’s new Chief Executive Officer. He will join Acadia on April
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call
AEVIS VICTORIA SA erzielte im Jahr 2021 ein sehr gutes Ergebnis mit ihren Beteiligungen, bei einem Ertrag von CHF 216.4 Millionen und einem Reingewinn von CHF 197.6 Millionen auf Holdingebene
AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million
DGAP-HV: Fresenius SE & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 13. Mai 2022 mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting on May 13, 2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
DGAP-HV: Fresenius Medical Care AG & Co. KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 12.05.2022 in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten mit dem Ziel der europaweiten Verbreitung
DGAP-AGM: Fresenius Medical Care AG & Co. KGaA: Announcement of the Convening of the General Meeting in Virtuelle Hauptversammlung ohne physische Präsenz der Aktionäre oder ihrer Bevollmächtigten on 12.05.2022 according to article 121 AktG (German S
DGAP-News: STRATEC SE: STRATEC GENERATES NEW RECORD SALES AND EARNINGS IN 2021 FINANCIAL YEAR
DGAP-News: STRATEC SE: STRATEC ERZIELT IM GESCHÄFTSJAHR 2021 NEUE REKORDWERTE BEI UMSATZ UND ERGEBNIS